BridgeMD
New treatment option for Lactation Suppressed
Official title Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion
ClinicalTrials.gov ID: NCT06123026
What this study is testing
What is Cabergoline?
Cabergoline is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for lactation suppressed.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 50, women only. Healthy volunteers may be eligible.
You may be able to join if
- pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine...
- ages 18 to 50
- con provide informed consent in English
You likely can't join if
- Age under 18 or above 50
- gestational ages before 16 weeks 0 days or after 20 weeks 0 days
- unable to provide written consent in English
- hypertensive disorder
- uncontrolled hypertension or known hypersensitivity to ergot derivatives
- History of cardiac valvular disorders
See the full eligibility criteria
- pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises
- ages 18 to 50
- con provide informed consent in English
- Age under 18 or above 50
- gestational ages before 16 weeks 0 days or after 20 weeks 0 days
- unable to provide written consent in English
- hypertensive disorder
- uncontrolled hypertension or known hypersensitivity to ergot derivatives
- History of cardiac valvular disorders
- history of pulmonary fibrosis
- documented bipolar schizophrenia
- documented allergy to medication, including lactose intolerance (placebo pill involves lactose)
The study team makes the final eligibility decision.
Where it's taking place
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 50 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.